1. Production, characterization and toxicology assay of creatine pegylated nanoliposome with polysorbate 80 for brain delivery
- Author
-
DIEGO B. BORIN, NATHANA J. MEZZOMO, RODRIGO A. VAUCHER, GUILHERME DO CARMO, LUIZ C. RODRIGUES JUNIOR, FERNANDO B. SULCZEWSKI, CLAITON I. SCHWERTZ, RICARDO E. MENDES, ADRIANI P. DAMIANI, VANESSA M. DE ANDRADE, VIRGÍNIA C. RECH, and CARINA R. BOECK
- Subjects
nanocarrier ,neurodegenerative diseases ,nanotechnology ,liposomes ,Science - Abstract
ABSTRACT Creatine acts intracellularly as energy buffer and storage, demonstrating protective effects in animal models of neurodegenerative diseases. However, its permeability throught blood-brain barrier (BBB) is reduced. The aim of the present study was developing a carrier to facilitate the delivery of creatine to the central nervous system. Creatine nanoliposomes were produced, characterized and assayed in models of toxicity in vitro and in vivo. Particles showed negative zeta potential (-12,5 mV), polydispersity index 0.237 and medium-size of 105 nm, which was confirmed by transmission electron microscopy (TEM) images. Toxicity assay in vitro was evaluated with blank liposomes (no drug) or creatine nanoliposomes at concentrations of 0.02 and 0.2 mg/mL, that did not influence the viability of Vero cells. The result. of the comet assay that the nanoliposomes are not genotoxic, togeher with cell viability demonstrated that the nanoliposomes are not toxic. Besides, in vivo assays not demonstrate toxicity in hematological and biochemical markers of young rats. Nevertheless, increase content of creatine in the cerebral cortex tissue after subchronic treatment was observed. Altogether, results indicate increase permeability of creatine to the BBB that could be used as assay for in vivo studies to confirm improved effect than free creatine.
- Published
- 2018
- Full Text
- View/download PDF